Ning Wu

Dr. Ning Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YLYuhang Liu
Yuhang Liu
YLYingfeng Li
Yingfeng Li
JLJingqi Li
Jingqi Li
HRHui Rao
Hui Rao
JSJianfei Sun
Jianfei Sun
NWNing Wu
Ning Wu

3 March 2025 in Infection
Verified
Journal Article
Closed access
PDF file
CTChao Tang
Chao Tang
RHRongshou Han
Rongshou Han
JYJiaxin Yang
Jiaxin Yang
NWNing Wu
Ning Wu
DHDian He
Dian He

1 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SWShouting Wu
Shouting Wu
XLXi Liang
Xi Liang
FLFang Luo
Fang Luo
HLHua Liu
Hua Liu
LSLingyi Shen
Lingyi Shen
CRCarl Redshaw
Carl Redshaw
A phenazine-1-carboxylic acid intermediate was synthesized from the reaction of aniline and 2-bromo-3-nitro-benzoic acid. It was then esterified and reacted with hydrazine hydrate to afford phenazine-1-carboxylic hydrazine. Finally, 10 new hydrazone compounds 3a–3j were obtained by the condensation reaction of phenazine-1-carboxylic acid hydrazide and the respective aldehyde-containing compound. The structures were characterized by 1H and 13C NMR spectroscopy, MS and single crystal X-ray diffraction. The antitumor activity of the target compounds in vitro (HeLa and A549) was determined by thiazolyl blue tetrazolium bromide. The results showed that compound (E)-N′-(2-hydroxy-4-(2-(piperidine-1-yl) ethoxy) benzyl) phenazine-1-carbonyl hydrazide 3d exhibited good cytotoxic activity.

19 September 2025 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ZJZhuojun Jiang
Zhuojun Jiang
JZJiancao Zuo
Jiancao Zuo
HLHailan Luo
Hailan Luo
YTYan Tang
Yan Tang
ZTZhuoting Tan
Zhuoting Tan
NWNing Wu
Ning Wu

2 May 2025 in Journal of Alzheimer's Disease Reports
Verified
Journal Article
Open access
BXBingyang Xu
Bingyang Xu
CTChao Tang
Chao Tang
RHRongshou Han
Rongshou Han
CZChaomin Zhu
Chaomin Zhu
YYYuxuan Yang
Yuxuan Yang
DHDian He
Dian He
An increasing body of evidence suggests neuroinflammation has a prominent role in the pathogenesis of Alzheimer's disease (AD). The amyloid-β-tau-neurodegeneration (ATN) classification system is now being expanded toward an amyloid-β-tau neurodegeneration-neuroinflammation (ATN(I)) system. Activated microglia and reactive astrocytes are the key hubs for neuroinflammation in AD, and chemokines are recognized as pivotal modulators of microglial innate immune functions. In this review, based on the chemokine-microglia regulatory axis, we elucidate the mechanisms through which chemokines influence microglial function, potentially modulating neurotoxicity or neuroprotection in AD. The key chemokines that significantly affect microglial polarization, such as CCL2, CCL3, and CXCL1, are summarized, and their role in disease progression are elaborated. Additionally, we explore prospective therapeutic interventions centered on the chemokine-microglia regulatory axis, offering valuable perspectives on pathobiology of AD and avenues for pharmacological advancements.

10 October 2025 in Functional & Integrative Genomics
Verified
Journal Article
Closed access
PDF file
YLYingfeng Li
Yingfeng Li
DWDesheng Wang
Desheng Wang
YLYuhang Liu
Yuhang Liu
CLChenyang Liu
Chenyang Liu
MCMeixi Chen
Meixi Chen
NWNing Wu
Ning Wu